Orchestra BioMed Inc.

2.67
-0.44 (-14.15%)
At close: Apr 04, 2025, 3:48 PM

Orchestra BioMed Statistics

Share Statistics

Orchestra BioMed has 38.31M shares outstanding. The number of shares has increased by 6.22% in one year.

Shares Outstanding 38.31M
Shares Change (YoY) 6.22%
Shares Change (QoQ) 0%
Owned by Institutions (%) n/a
Shares Floating 26.92M
Failed to Deliver (FTD) Shares 48
FTD / Avg. Volume 0.08%

Short Selling Information

The latest short interest is 736.73K, so 1.94% of the outstanding shares have been sold short.

Short Interest 736.73K
Short % of Shares Out 1.94%
Short % of Float 2.79%
Short Ratio (days to cover) 4.06

Valuation Ratios

The PE ratio is -2413.54 and the forward PE ratio is -2.79. Orchestra BioMed's PEG ratio is 24.16.

PE Ratio -2413.54
Forward PE -2.79
PS Ratio 55831.75
Forward PS 6.7
PB Ratio 4468.84
P/FCF Ratio -2896.61
PEG Ratio 24.16
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Orchestra BioMed.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.27, with a Debt / Equity ratio of 0.07.

Current Ratio 4.27
Quick Ratio 4.26
Debt / Equity 0.07
Debt / EBITDA -0.03
Debt / FCF -0.04
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $37.69K
Profits Per Employee $-871.77K
Employee Count 70
Asset Turnover 0.03
Inventory Turnover 1.18

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -36.22% in the last 52 weeks. The beta is 0.62, so Orchestra BioMed's price volatility has been higher than the market average.

Beta 0.62
52-Week Price Change -36.22%
50-Day Moving Average 4.76
200-Day Moving Average 5.67
Relative Strength Index (RSI) 32.08
Average Volume (20 Days) 62.57K

Income Statement

In the last 12 months, Orchestra BioMed had revenue of 2.64M and earned -61.02M in profits. Earnings per share was 0.

Revenue 2.64M
Gross Profit 2.43M
Operating Income -64.3M
Net Income -61.02M
EBITDA -64.3M
EBIT n/a
Earnings Per Share (EPS) 0
Full Income Statement

Balance Sheet

The company has 22.26M in cash and 2.24M in debt, giving a net cash position of 20.02M.

Cash & Cash Equivalents 22.26M
Total Debt 2.24M
Net Cash 20.02M
Retained Earnings -309.88M
Total Assets 76.17M
Working Capital 52.96M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -50.56M and capital expenditures -289K, giving a free cash flow of -50.85M.

Operating Cash Flow -50.56M
Capital Expenditures -289K
Free Cash Flow -50.85M
FCF Per Share 0
Full Cash Flow Statement

Margins

Gross margin is 92.27%, with operating and profit margins of -2437.49% and -2313.27%.

Gross Margin 92.27%
Operating Margin -2437.49%
Pretax Margin -2313.27%
Profit Margin -2313.27%
EBITDA Margin -2437.49%
EBIT Margin -2437.49%
FCF Margin -1927.48%

Dividends & Yields

OBIO does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for OBIO is $14.5, which is 357.4% higher than the current price. The consensus rating is "Buy".

Price Target $14.5
Price Target Difference 357.4%
Analyst Consensus Buy
Analyst Count 5
Stock Forecasts

Scores

Altman Z-Score -5.88
Piotroski F-Score 3